HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline Abreva $10 Mil. Sales Help Offset Smoking Cessation Woes

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline's Abreva posted $10 mil. in sales during the OTC cold sore medication's first full quarter on the U.S. market.

You may also be interested in...



Block Boosts GSK Consumer Group In Q2, Offsets NicoDerm, Nicorette Losses

GlaxoSmithKline's consumer healthcare sales rose 19% to $1.15 bil. in the second quarter due to the addition of Block Drug's OTC portfolio. Excluding Block revenue, sales declined 2%, largely reflecting the firm's faltering smoking cessation business.

Whitehall Dimetapp Reformulations, New Products Drive U.S. Growth

Whitehall-Robins' quick reformulation and shipment of PPA-free Dimetapp products spurred a 50.3% increase in the brand's domestic sales during the first quarter. Dimetapp sales reached $23.6 mil. in the U.S., compared to $15.7 mil. in the year-ago period, Whitehall parent American Home Products said April 25.

Abreva Shortened Healing Time, Duration Of Cold Sores Stressed In Promos

SmithKline Beecham's Abreva, now hitting shelves in food, drug and mass outlets, is the first OTC indicated for shortening the healing time and duration of symptoms related to cold sores and fever blisters.

Topics

UsernamePublicRestriction

Register

RS132240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel